Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Equivalence of Altebrel vs Enbrel in Healthy Subjects
NCT03273088Phase 1Completed
- Sponsor
- AryoGen Biopharma
- Start
- Dec 2016
- Primary completion
- Mar 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Altebrel in rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and 2 more (2 arms), sponsored by AryoGen Biopharma. Primary endpoints: Area under the serum concentration time curve from time 0 extrapolated to infinity at 21 days and Maximum serum concentration at 21 days. Started Dec 2016; status: completed.
02
Drugs
Altebrel
03
Conditions
rheumatoid arthritis (RA)ankylosing spondylitis (AS)psoriatic arthritis (PsA)plaque psoriasisjuvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT03273088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03273088.